Biotech stock swoon sparks buyout interest: investor
May 04, 2016 at 07:03 AM EDT
NEW YORK (Reuters) - A brutal start to the year for biotech stocks could pave the way for more deal-making in the sector, with premiums of potentially 50 percent to 100 percent above depressed share prices, according to a top healthcare investor.
